MPO and bronchopulmonary dysplasia: Using our novel reversible MPO inhibitor—N-acetyl-lysyltyrosylcysteine amide (KYC)—as a research probe, we have identified that a systems pharmacology approach offers a promising new perspective on BPD treatment.